Month: January 2024

TORONTO, Jan. 22, 2024 (GLOBE NEWSWIRE) — Madison Metals Inc. (“Madison” or the “Company”) (CSE: GREN) (OTCQB: MMTLF) (FSE: 4EF0) is pleased to provide an update on its uranium forward sales agreement with Sanmiguel Capital Investment (Bahamas) Ltd., a financial advisory firm assisting with the administration. Since November 2023, Madison Metals has successfully received funds for its first tranche of the Company’s forward sales agreement, at an average price of US$68 per lb. This achievement underscores the uranium agreement’s effectiveness in securing favorable pricing, well above the contractual established US$45 price floor. As there is no price ceiling, Madison’s forward sales agreement provides upside potential for advantageous pricing as the market continues to surge. The significant flexibility of the forward sales agreement...

ZUG, Switzerland, Jan. 22, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for deucrictibant for the prophylactic treatment of HAE attacks following review of data from a 26-week rodent toxicology study. “The lift of the clinical hold in the U.S. enables us to progress the global development of deucrictibant for long-term prophylaxis, including resuming the open-label portion of CHAPTER-1, our Phase 2 proof-of-concept study of deucrictibant for the prevention of HAE attacks, in the U.S.,” said Berndt Modig, Chief Executive Officer of Pharvaris. “We are...

Issues Open Letter to Shareholders NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today issued a letter to shareholders highlighting steps the Company is continuing to take to drive sustainable, long-term shareholder value. The full text of the letter follows: Dear Fellow Shareholders, We are writing today with an update on the important steps we continue to take at Genco to drive sustainable, long-term shareholder value for you. Over the last several years, our Board of Directors and management team have navigated various market environments, exhibited a disciplined approach to capital allocation and overseen the successful transformation of the Company while...

Temecula, CA , Jan. 22, 2024 (GLOBE NEWSWIRE) — Global Warming Solutions, Inc. (OTCQB: GWSO), a pioneer in developing advanced technologies that combat climate change, is excited to announce the appointment of Dr. Jason McKenna to its Advisory Board. This strategic addition underlines our commitment to leading the charge against global climate challenges through innovative solutions. Dr. McKenna, a distinguished figure with over 25 years of experience in national security R&D, hydrocarbon exploration, and renewable energy technologies, including hydrogen production and storage, brings a wealth of knowledge to GWSO. Dr. McKenna is poised to make significant contributions to our mission with his Ph.D. in Geophysics from Southern Methodist University and his role as Director of RDTE&T at the University of Southern Mississippi’s...

Positive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (PTSD), with a discussion with the U.S. Food & Drug Administration (FDA) anticipated in Q2’24. Positive End of Phase 2b (EoP2) meeting with FDA announced for BNC210 in Social Anxiety Disorder (SAD) following the Phase 3-enabling PREVAIL Phase 2 trial data readout. The Company is actively engaged in strategic partnership discussions with interested parties for multiple pipeline assets and is evaluating options to proceed with clinical development plans for BNC210 in both PTSD and SAD. ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class,...

Table 1.Summary table for historical drill holes Bz6, Bz16 and Bz20 from the Berezski East Target, Elemes ProjectFigure 1.Arras Minerals License Package (Pavlodar, Kazakhstan)Figure 2.Location of the three holes re-assayed by Arras at the Berezski East project, Elemes Project. Collars for all historical drilling are shown.Figure 3.The Location of the Berezski East target in relation to the Quartzite Gorka and Karagandy-Ozek targets previously announced by Arras Minerals. Intense alteration and widespread surface mineralization across a 5-kilometer strike is indicating a big, largely untested porphyry system in the Elemes Licence area.VANCOUVER, British Columbia, Jan. 22, 2024 (GLOBE NEWSWIRE) — Arras Minerals Corp. (TSX-V: ARK) (“Arras” or “the Company”) is pleased to announce the results from...

Figure 1Stallion Uranium’s Eastern Basin ProjectsVANCOUVER, British Columbia, Jan. 22, 2024 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: HM40) is pleased to announce that the Company has entered into a non-binding letter of intent (the “LOI”), under which the Company has granted an unnamed party (the “Optionor”) the option to acquire a 100% interest in its Eastern Basin Projects, comprising seven (7) mineral claims totalling approximately 10,874 hectares (25,870 acres) and located in the Province of Saskatchewan (the “Property”). “The sale of Stallion’s eastern Athabasca Basin projects allow the Company to focus on our core projects in the Western Athabasca Basin while seeing these projects advanced,” commented Drew Zimmerman, CEO. “We...

MELBOURNE, Australia, Jan. 22, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA (US) from 25 – 27 January 2024. Dr David N. Cade, Telix Group Chief Medical Officer, said, “We are pleased to present updates on our late-stage therapeutic programs for prostate and kidney cancer at ASCO GU 2024, the leading specialised event for GU cancer care worldwide. “The ProstACT GLOBAL study of TLX591 (177Lu rosopatamab tetraxetan) will be presented, the first Phase III trial to evaluate TLX591, our lead radio-antibody drug conjugate (rADC) therapy candidate in patients with PSMA-positive metastatic castrate-resistant...